Connected Cardiology to Control Cardiac Rythm
NCT: NCT06091514 · WITHDRAWN
Brief Summary
New-onset of atrial fibrillation (AF) and atrial arrythmia (AA) in general, is important as it exposes patients to stroke or other embolic complications not to mention the risk of heart failure. AF detection in high risk populations such as patients with a recent stroke or TIA or, symptomatic patients with multiple risk factors for AF, is performed with long-term electrocardiography monitoring using frequently implantable loop recorders (ILR). These recorders have their own limitations related to the invasive nature of the device implanted under the skin of the chest with limited acceptation by the patients. Smart watches appear as useful alternatives, but they need to be evaluated in an all-comer population of patients highly exposed to AF, different from the large population studies conducted in healthy young adults with a low incidence of AF. The unique features of CardiacSense Medical System suggest that we could have an accurate noninvasive detection of AF in a selected population very much exposed to the risk of atrial fibrillation, the most frequent atrial arrhythmia.
Frequently Asked Questions
What is Connected Cardiology to Control Cardiac Rythm?
Connected Cardiology to Control Cardiac Rythm is a clinical trial registered under NCT06091514. Current status: WITHDRAWN.
What is the status of NCT06091514?
The current status of NCT06091514 (Connected Cardiology to Control Cardiac Rythm) is: WITHDRAWN.
When did Connected Cardiology to Control Cardiac Rythm start?
Connected Cardiology to Control Cardiac Rythm started on 2024-02.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.